Variant Summary
- HGVS
- —
- Variant Type(s)
- transcript_amplification
- Evidence Items
- 30
Evidence Level Distribution
Level B: 17Level C: 5Level D: 8
Evidence Items
Showing CIViC evidence rows where gene = FGFR1 and variant = Amplification.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| B | Prognostic | Supports | Poor Outcome | Breast Cancer | 5 | |
| B | Prognostic | Supports | Poor Outcome | Breast Cancer | 5 | |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Fulvestrant,Rogaratinib,Palbociclib | 5 |
| D | Predictive | Supports | Sensitivity/Response | Lung Squamous Cell Carcinoma | PD173074 | 5 |
| B | Prognostic | Supports | Poor Outcome | Lung Squamous Cell Carcinoma | 4 | |
| B | Prognostic | Supports | Poor Outcome | Cancer | 4 | |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | PD173074 | 4 |
| B | Prognostic | Does Not Support | Poor Outcome | Lung Squamous Cell Carcinoma | 4 | |
| D | Predictive | Supports | Resistance | Breast Cancer | Afimoxifene | 3 |
| D | Predictive | Supports | Sensitivity/Response | Ewing Sarcoma Of Bone | Ponatinib | 3 |
| B | Prognostic | Supports | Poor Outcome | Breast Cancer | 3 | |
| B | Predictive | Supports | Sensitivity/Response | Breast Cancer | Everolimus,Endocrine Drug Therapy | 3 |
| C | Predictive | Does Not Support | Sensitivity/Response | Breast Cancer | Pemigatinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Futibatinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Estrogen-receptor Positive Breast Cancer | Ponatinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Squamous Cell Carcinoma | Infigratinib | 3 |
| B | Prognostic | Supports | Poor Outcome | Lung Squamous Cell Carcinoma | 3 | |
| B | Predictive | Supports | Sensitivity/Response | Breast Cancer | Lucitanib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Adenosquamous Lung Carcinoma | Pazopanib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Breast Cancer | Erdafitinib | 2 |
| B | Predictive | Supports | Sensitivity/Response | Breast Cancer | Dovitinib | 2 |
| B | Predictive | Does Not Support | Sensitivity/Response | Breast Cancer | Sunitinib | 2 |
| D | Predictive | Supports | Breast Cancer | Lucitanib,Rogaratinib | 2 | |
| B | Predictive | Supports | Sensitivity/Response | Breast Cancer | Dovitinib | 2 |
| B | Predictive | Does Not Support | Resistance | Breast Cancer | Infigratinib | 2 |
| C | Predictive | Does Not Support | Sensitivity/Response | Bladder Carcinoma | Infigratinib | 2 |
| C | Predictive | Supports | Sensitivity/Response | Breast Cancer | Fexagratinib | 2 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Dovitinib | 2 |
| B | Prognostic | Supports | Better Outcome | Lung Non-small Cell Carcinoma | 2 | |
| C | Predictive | Supports | Sensitivity/Response | Breast Cancer | Pazopanib | 2 |